Library
1Fe-LSD
1Fe-LSD, also known as 1-(ferrocenecarbonyl)-LSD or as SYN-L-234, is a psychedelic drug of the lysergamide family related to lysergic acid diethylamide (LSD). It is thought to be a prodrug of LSD. The drug was patented by Lizard Labs in 2024. Subsequently, it was encountered online as a novel designer drug being sold in Germany in November 2025. 1Fe-LSD as the hemi-L-tartrate salt has been sold in the form of blotter containing 200 μg per tab and micropills containing 300 μg per pill. 1Fe-LSD is not an explicitly controlled substance in the United States or in Canada.
Classification
- Chemical: Lysergamide
- Psychoactive: Psychedelic
Effects
- Dilated Pupils
- Pupil Dilation
- Stimulation
- Nausea
- Spontaneous Tactile Sensations
- Introspection
- Time Distortion
- Conceptual Thinking
- Novelty Enhancement
- Analysis Enhancement
- Visual Distortions
- Color Enhancement
- Drifting
- Tracers
- Pattern Recognition Enhancement
Routes of Administration
No route information available yet.
Harm Reduction
Check interactions before mixing substances, pay attention to dose spacing and hydration, and treat all dosage guidance as approximate rather than guaranteed safe.
Sources
Substance data is aggregated from the following public harm-reduction and reference sources.
Links
This static page is intended as a readable non-JS and prerender-friendly library export.
